Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
RAND Corporation, Santa Monica, California.
J Am Geriatr Soc. 2019 Dec;67(12):2600-2604. doi: 10.1111/jgs.16117. Epub 2019 Sep 5.
BACKGROUND: Older adults are particularly vulnerable to complications from proton pump inhibitor (PPI) drugs. We sought to characterize the prevalence of potentially low-value PPI prescriptions among older adults to inform a quality improvement (QI) intervention. METHODS: We created a cohort of patients, aged 65 years or older, receiving primary care at a large academic health system in 2018. We identified patients currently prescribed any PPI using the electronic health record (EHR) medication list (current defined as September 1, 2018). A geriatrician, a gastroenterologist, a QI expert, and two primary care physicians (PCPs) created multidisciplinary PPI appropriateness criteria based on evidenced-based guidelines. Supervised by a gastroenterologist and PCP, two internal medicine residents conducted manual chart reviews in a random sample of 399 patients prescribed PPIs. We considered prescriptions potentially low value if they lacked a guideline-based (1) short-term indication (gastroesophageal reflux disease [GERD]/peptic ulcer disease/Helicobacter pylori gastritis/dyspepsia) or (2) long-term (>8 weeks) indication (severe/refractory GERD/erosive esophagitis/Barrett esophagus/esophageal adenocarcinoma/esophageal stricture/high gastrointestinal bleeding risk/Zollinger-Ellison syndrome). We used the Wilson score method to calculate 95% confidence intervals (CIs) on low-value PPI prescription prevalence. RESULTS: Among 69 352 older adults, 8729 (12.6%) were prescribed a PPI. In the sample of 399 patients prescribed PPIs, 63.9% were female; their mean age was 76.2 years, and they were seen by 169 PCPs. Of the 399 prescriptions, 143 (35.8%; 95% CI = 31.3%-40.7%) were potentially low value-of which 82% began appropriately (eg, GERD) but then continued long term without a guideline-based indication. Among 169 PCPs, 32 (18.9%) contributed to 59.2% of potentially low-value prescriptions. CONCLUSION: One in eight older adults were prescribed a PPI, and over one-third of prescriptions were potentially low-value. Most often, appropriate short-term prescriptions became potentially low value because they lacked long-term indications. With most potentially low-value prescribing concentrated among a small subset of PCPs, interventions targeting them and/or applying EHR-based automatic stopping rules may protect older adults from harm. J Am Geriatr Soc 67:2600-2604, 2019.
背景:老年人尤其容易受到质子泵抑制剂 (PPI) 药物并发症的影响。我们旨在描述老年人中潜在低价值 PPI 处方的流行情况,为质量改进 (QI) 干预提供信息。
方法:我们创建了一个队列,纳入了 2018 年在一家大型学术医疗系统接受初级保健的年龄在 65 岁或以上的患者。我们使用电子健康记录 (EHR) 药物清单确定目前正在服用任何 PPI 的患者(当前定义为 2018 年 9 月 1 日)。一位老年病专家、一位胃肠病专家、一位 QI 专家和两位初级保健医生 (PCP) 根据循证指南制定了多学科 PPI 适宜性标准。在一位胃肠病专家和一位 PCP 的监督下,两名内科住院医师对随机抽取的 399 名服用 PPI 的患者进行了手动病历审查。如果处方缺乏基于指南的 (1) 短期指征(胃食管反流病 [GERD]/消化性溃疡病/幽门螺杆菌胃炎/消化不良)或 (2) 长期 (>8 周) 指征(严重/难治性 GERD/腐蚀性食管炎/ Barrett 食管/食管腺癌/食管狭窄/高胃肠道出血风险/Zollinger-Ellison 综合征),我们认为处方具有潜在的低价值。我们使用 Wilson 评分法计算低价值 PPI 处方流行率的 95%置信区间 (CI)。
结果:在 69352 名老年人中,8729 名 (12.6%) 开具了 PPI。在服用 PPI 的 399 名患者中,63.9%为女性;他们的平均年龄为 76.2 岁,由 169 名 PCP 就诊。在 399 个处方中,143 个 (35.8%;95%CI=31.3%-40.7%) 可能具有较低的价值——其中 82%的处方开始时是合理的(例如 GERD),但随后缺乏基于指南的指征而长期使用。在 169 名 PCP 中,32 名 (18.9%) 开具了 59.2%的潜在低价值处方。
结论:八分之一的老年人开具了 PPI,超过三分之一的处方可能具有较低的价值。大多数情况下,适当的短期处方变得具有潜在的低价值,因为它们缺乏长期指征。由于大多数潜在低价值的处方集中在一小部分 PCP 中,因此针对他们的干预措施和/或应用基于 EHR 的自动停止规则可能会保护老年人免受伤害。美国老年医学会 67:2600-2604, 2019.
J Am Geriatr Soc. 2019-9-5
Cochrane Database Syst Rev. 2017-3-16
J Am Med Dir Assoc. 2016-7-1
J Am Med Dir Assoc. 2021-1
J Prim Health Care. 2016-6
Eur J Clin Pharmacol. 2023-9
JAMA Netw Open. 2023-2-1
Br J Gen Pract. 2022-5
JAMA Intern Med. 2019-9-1
Health Aff (Millwood). 2018-11
BMJ Qual Saf. 2018-5
Health Aff (Millwood). 2017-10-1
Ther Adv Drug Saf. 2017-9
Gastroenterology. 2017-8-5
Cochrane Database Syst Rev. 2017-3-16